Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies

Dasatinib is the 2nd generation TKI (Tyrosine Kinase Inhibitor) having the potential to treat numerous forms of leukemic and cancer patients and it is 300 times more potent than imatinib. Cancer is the major cause of death globally and need to enumerate novel strategies to coping with it. Various novel therapeutics introduced into the market for ease in treating various forms of cancer. We reviewed and evaluated all the related aspects of dasatinib, which can enhance the knowledge about dasatinib therapeutics methodology, pharmacodynamic and pharmacokinetics, side effects, advantages, disadvantages, various kinds of interactions and its novel formulations as well.

Automated summary

Dasatinib is a potent second generation TKI that shows promise in treating various forms of leukemia and cancer, being 300 times more potent than imatinib. With cancer being a leading cause of death worldwide, it is crucial to explore novel strategies to combat this disease. This review provides an evaluation of dasatinib, covering its therapeutic methodology, pharmacodynamics and pharmacokinetics, side effects, advantages, disadvantages, various interactions, and novel formulations.